SAN DIEGO, Oct. 17 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. today reported financial results for the quarter ended September 30, 2007. The Company reported total revenue of $190.0 million for the third quarter, including net product sales of $177.4 million. Net loss for the quarter ended September 30, 2007 was $39.8 million, or $0.30 per share. At September 30, 2007, the Company held cash, cash equivalents and short-term investments of approximately $1.1 billion.
“BYETTA and SYMLIN, our first-in-class diabetes medicines, have been on the market for nearly 30 months and continued to show growth in physician adoption, prescriptions and reported revenue in the third quarter,” said Daniel M. Bradbury, President and Chief Executive Officer of Amylin Pharmaceuticals. “Additionally we continued to advance our pipeline drug candidates and remain on track to report key clinical data later this quarter from our once-weekly exenatide long-acting release program and our integrated neurohormone obesity program.”
Quarter ended September 30, 2007
Net product sales of $177.4 million for the third quarter include $161.1 million for BYETTA(R) (exenatide) injection and $16.3 million for SYMLIN(R) (pramlintide acetate) injection. This compares to net product sales of $138.8 million, consisting of $126.4 million for BYETTA and $12.4 million for SYMLIN for the same period in 2006.
Revenues under collaborative agreements were $12.6 million for the quarter ended September 30, 2007, compared to $8.2 million for the same period in 2006. The increase reflects higher cost-sharing payments from Lilly to equalize development expenses for BYETTA and exenatide long-acting release (LAR).
Selling, general and administrative expenses increased to $87.7 million for the quarter ended September 30, 2007, compared to $69.0 million for the same period in 2006. The increase reflects higher promotional expenses for BYETTA and SYMLIN, increased expenses associated with the Company’s expanded field force, and increased business infrastructure to support the Company’s growth.
Research and development expenses increased to $61.5 million for the quarter ended September 30, 2007, compared to $53.7 million for the same period in 2006. The increase primarily reflects increased development expenses for exenatide LAR and ongoing costs associated with the advancement of the Company’s obesity development programs.
Collaborative profit sharing, which represents Lilly’s share of the gross margin for BYETTA, was $75.0 million for the quarter ended September 30, 2007, compared to $57.0 million for the same period in 2006.
Net loss for the quarter ended September 30, 2007 was $39.8 million, or $0.30 per share, compared to $46.1 million, or $0.36 per share, for the same period in 2006. Net loss for the quarter ended September 30, 2006 included a $7.9 million non-operating charge related to a make-whole payment associated with the early redemption of convertible senior debt in August 2006.
Nine months ended September 30, 2007
Total revenues for the nine months ended September 30, 2007 were $559.0 million. This includes net product sales of $506.7 million, including $459.7 million for BYETTA and $47.0 million for SYMLIN. This compares to net product sales of $323.5 million, consisting of $293.2 million for BYETTA and $30.3 million for SYMLIN for the same period in 2006.
Revenues under collaborative agreements were $52.2 million for the nine months ended September 30, 2007, compared to $24.1 million for the same period in 2006. The increase reflects $15 million in milestones associated primarily with the launch of BYETTA in the European Union during the second quarter of 2007 and higher cost-sharing payments to equalize development expenses for BYETTA and exenatide LAR.
Selling, general and administrative expenses increased to $268.6 million for the nine months ended September 30, 2007, from $192.4 million for the same period in 2006. The increase reflects higher promotional expenses for BYETTA and SYMLIN, costs associated with the Company’s expanded sales force and increased business infrastructure to support the Company’s growth.
Research and development expenses increased to $192.7 million for the nine months ended September 30, 2007, from $155.9 million for the same period in 2006. The increase primarily reflects costs associated with the development of exenatide LAR and costs associated with the Company’s obesity programs.
Collaborative profit sharing was $212.3 million for the nine months ended September 30, 2007, compared to $130.4 million for the same period in 2006.
Net loss was $134.2 million, or $1.02 per share for the nine months ended September 30, 2007, compared to $160.4 million, or $1.33 per share, for the same period in 2006.
Conference Call
Amylin will webcast its Quarterly Update Conference Call today at 5:00 p.m. ET/2:00 p.m. PT. The call will be webcast live through Amylin’s corporate website, http://www.amylin.com, and a recording will be made available following the close of the call.
Daniel M. Bradbury, Amylin’s President and Chief Executive Officer will lead the call. During the call, the Company plans to provide further details underlying its third quarter financial results, and information regarding assumptions for the remainder of 2007 operations. For those without access to the Internet, the live call may be accessed by phone by calling (866) 700-6979 (domestic) or (617) 213-8836 (international), passcode 48312438. A replay of the call will also be available by phone for 24 hours beginning approximately one hour after the close of the call and can be accessed at (888) 286-8010 (domestic) or (617) 801-6888 (international), passcode 10940869.
About Amylin
Amylin Pharmaceuticals is a biopharmaceutical company committed to improving lives through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide) injection. Amylin’s research and development activities leverage the company’s expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is located in San Diego, California with over 1,800 employees nationwide. Further information on Amylin Pharmaceuticals is available at http://www.amylin.com.
This press release contains forward-looking statements about Amylin, which involve risks and uncertainties. The Company’s actual results could differ materially from those discussed herein due to a number of risks and uncertainties, including risks that BYETTA or SYMLIN may be affected by competition, unexpected new data, technical issues, or manufacturing and supply issues; risks that our financial results may fluctuate significantly from period to period and may not meet market expectations; risks that our clinical trials will not be completed when planned or may not replicate previous results; risks that our preclinical studies may not be predictive; risks that the FDA may not approve the Company’s sNDAs or product candidates; risks that we may not be able to complete our manufacturing facility on a timely basis; and other risks inherent in the drug development and commercialization process. Commercial and government reimbursement and pricing decisions and the pace of market acceptance may also affect the potential for BYETTA or SYMLIN. These and additional risks and uncertainties are described more fully in the Company’s recently filed Form 10-Q. Amylin disclaims any obligation to update these forward-looking statements.
CONTACT: Mark Foletta, Senior Vice President, Finance and Chief Financial
Officer of Amylin Pharmaceuticals, Inc., +1-858-552-2200
Web site: http://www.amylin.com/
